
Adjuvant nivolumab versus placebo in high-risk muscle invasive urothelial carcinoma
Approximately one in five urothelial carcinomas are muscle-invasive at initial diagnosis.1 Standard management for muscle-invasive urothelial carcinoma (MIUC) is bladder sparing therapy or radical...